Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin's REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
On Track to Report REDUCE-IT Results Before the End of Q3 2018
View HTML
Toggle Summary Amarin Sponsors Two Scientific Presentations Scheduled for National Kidney Foundation 2018 Spring Clinical Meetings
BEDMINSTER, N.J. and DUBLIN, Ireland , March 29, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health,  is supporting the presentation of two accepted scientific
View HTML
Toggle Summary Amarin to Present at the H.C. Wainwright Annual Global Life Sciences Conference
BEDMINSTER, N.J. and DUBLIN, Ireland , March 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin Commemorates National Triglycerides Day on March 28
Increasing Awareness of Triglycerides and a Call to Action for People to Talk to Their Doctors, Nurses & Pharmacists About Their Triglyceride Levels
View HTML
Toggle Summary Amarin Announces First Middle East Approval for Vascepa®
Lebanon Approves Vascepa for Sale, First in Series of Anticipated Approvals
View HTML
Toggle Summary Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP)
BEDMINSTER , N.J. and DUBLIN, Ireland , March 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, presented an analysis showing that, consistent with
View HTML
Toggle Summary Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs
BEDMINSTER, N.J. and DUBLIN, Ireland , March 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, announced the presentation of  a poster today at the
View HTML
Toggle Summary Amarin Announces Closing of Underwriter's Purchase of Additional Shares
BEDMINSTER, N.J. , and DUBLIN, Ireland , March 05, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"), it has issued 1,438,356 additional ADSs, pursuant
View HTML
Toggle Summary Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study
Study Results Anticipated to be Released by End of Q3 2018
View HTML
Toggle Summary Amarin Sponsors Multiple Scientific Presentations Scheduled for 2018 American College of Cardiology Annual Scientific Session & Expo
Presentations to Include Additional Real-World Data, Clinical and Cost Analyses of Patient Outcomes From Managed Care Databases
View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation